Proceedings of the II National Academic Congress of Dermatology
January 2022
Research cited in this study
8 / 8 results
research Prevalence of Telogen Effluvium Hair Loss in COVID-19 Patients and Its Relationship with Disease Severity
COVID-19 patients may experience hair loss, but it's not linked to their age or sex.
research Two Phase 3 Trials of Baricitinib for Alopecia Areata
Baricitinib was effective in treating alopecia areata in two major trials.
research A Systematic Review of Acute Telogen Effluvium, a Harrowing Post-COVID-19 Manifestation
COVID-19 can cause a type of hair loss that usually starts 74 days after infection, affecting mostly women, but most patients eventually recover.
research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
research Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options
The document concludes that while there are various treatments for Alopecia Areata, there is no cure, and individualized treatment plans are essential due to varying effectiveness.
research A Surge in the Incidence of Telogen Effluvium in Minority Predominant Communities Heavily Impacted by COVID-19
More people, especially Hispanic/Latinx, in certain NYC communities experienced temporary hair loss during the COVID-19 pandemic.
research Alopecia Areata: A Multifactorial Autoimmune Condition
Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.